Avalon GloboCare (NASDAQ:CHGA) Stock Price Down 0.4% – What’s Next?

Shares of Avalon GloboCare Corp. (NASDAQ:CHGA) fell 0.4% on Friday . The company traded as low as $2.2912 and last traded at $2.42. 34,945 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 408,785 shares. The stock had previously closed at $2.43.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Avalon GloboCare from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, August 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Avalon GloboCare presently has a consensus rating of “Sell”.

Avalon GloboCare Stock Performance

The stock’s 50-day simple moving average is $5.10 and its two-hundred day simple moving average is $8.31. The stock has a market cap of $2.30 million, a price-to-earnings ratio of -3.51 and a beta of -0.05.

Avalon GloboCare (NASDAQ:CHGA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($2.80) earnings per share (EPS) for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.